Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederroche.com
Investor Update
Get the latest updates from Investor Update directly as they happen.
Follow now 318 followers
Latest posts
Last updated about 13 hours ago
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy
about 13 hours ago
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options...
Reminder: Invitation to Roche’s Virtual Investor Event at EASD
7 days ago
We are pleased to invite investors and analysts to participate in our...
Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis
9 days ago
New Phase II data show vast majority of patients experiencing no relapses...
Invitation to Roche’s Pharma Day 2024
14 days ago
The Roche Investor Relations team would like to invite you to the...
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH
18 days ago
With the option to self-administer, PiaSky® (crovalimab) has the potential to reduce...
Invitation to Roche’s Virtual Investor Event at EASD
21 days ago
We are pleased to invite investors and analysts to participate in our...
European Commission approves Roche’s Vabysmo for treatment of retinal vein occlusion (RVO)
about 2 months ago
Approval is based on data from two Phase III studies in branch...
Roche closes acquisition of LumiraDx’s Point of Care technology to expand access to diagnostic testing in primary care
about 2 months ago
The acquisition of LumiraDx’s Point of Care technology received all required antitrust...
[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 5% (CER) in first half of 2024; strong growth in second quarter – full-year earnings outlook raised
about 2 months ago
Group sales were up by 5%1 at constant exchange rates (CER) (stable...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
about 2 months ago
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as...
Reminder: Invitation to Roche’s Half Year Results 2024 Presentation
about 2 months ago
Roche will publish its Half Year Results of 2024 prior to the...
Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
about 2 months ago
More than 90% of patients had absence of DME after four years...